Irinotecan in small-cell lung cancer

Current data

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Irinotecan, a new topoisomerase I inhibitor, has significant activity in the treatment of untreated and previously treated patients with small-cell lung cancer (SCLC). In combination with cisplatin, a Japanese randomized trial showed a statistically significant survival advantage over cisplatin/etoposide in chemotherapy-naive patients with extensive-stage disease. This represents the first major advance in the treatment of extensive-stage SCLC in 20 years. Randomized trials in the United States are underway to confirm these impressive results. Meanwhile, trials incorporating irinotecan and cisplatin into treatment regimens for limited-stage disease are being conducted. Furthermore, irinotecan-containing regimens with other agents such as carboplatin, etoposide, and paclitaxel in first- or second-line therapies for SCLC are being evaluated. Preliminary results are encouraging. This article will highlight the exciting results achieved with irinotecan in SCLC and discuss its promising future in this disease.

Original languageEnglish (US)
JournalClinical Lung Cancer
Volume2
Issue numberSUPPL. 2
StatePublished - 2001
Externally publishedYes

Fingerprint

irinotecan
Small Cell Lung Carcinoma
Cisplatin
Etoposide
Topoisomerase I Inhibitors
Carboplatin
Therapeutics
Paclitaxel
Drug Therapy
Survival

Keywords

  • Chemotherapy
  • CPT-11
  • Irinotecan
  • Lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Pulmonary and Respiratory Medicine

Cite this

Irinotecan in small-cell lung cancer : Current data. / Kelly, Karen.

In: Clinical Lung Cancer, Vol. 2, No. SUPPL. 2, 2001.

Research output: Contribution to journalArticle

@article{ae73486b904d475ab6e61489d448e3b9,
title = "Irinotecan in small-cell lung cancer: Current data",
abstract = "Irinotecan, a new topoisomerase I inhibitor, has significant activity in the treatment of untreated and previously treated patients with small-cell lung cancer (SCLC). In combination with cisplatin, a Japanese randomized trial showed a statistically significant survival advantage over cisplatin/etoposide in chemotherapy-naive patients with extensive-stage disease. This represents the first major advance in the treatment of extensive-stage SCLC in 20 years. Randomized trials in the United States are underway to confirm these impressive results. Meanwhile, trials incorporating irinotecan and cisplatin into treatment regimens for limited-stage disease are being conducted. Furthermore, irinotecan-containing regimens with other agents such as carboplatin, etoposide, and paclitaxel in first- or second-line therapies for SCLC are being evaluated. Preliminary results are encouraging. This article will highlight the exciting results achieved with irinotecan in SCLC and discuss its promising future in this disease.",
keywords = "Chemotherapy, CPT-11, Irinotecan, Lung cancer",
author = "Karen Kelly",
year = "2001",
language = "English (US)",
volume = "2",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Irinotecan in small-cell lung cancer

T2 - Current data

AU - Kelly, Karen

PY - 2001

Y1 - 2001

N2 - Irinotecan, a new topoisomerase I inhibitor, has significant activity in the treatment of untreated and previously treated patients with small-cell lung cancer (SCLC). In combination with cisplatin, a Japanese randomized trial showed a statistically significant survival advantage over cisplatin/etoposide in chemotherapy-naive patients with extensive-stage disease. This represents the first major advance in the treatment of extensive-stage SCLC in 20 years. Randomized trials in the United States are underway to confirm these impressive results. Meanwhile, trials incorporating irinotecan and cisplatin into treatment regimens for limited-stage disease are being conducted. Furthermore, irinotecan-containing regimens with other agents such as carboplatin, etoposide, and paclitaxel in first- or second-line therapies for SCLC are being evaluated. Preliminary results are encouraging. This article will highlight the exciting results achieved with irinotecan in SCLC and discuss its promising future in this disease.

AB - Irinotecan, a new topoisomerase I inhibitor, has significant activity in the treatment of untreated and previously treated patients with small-cell lung cancer (SCLC). In combination with cisplatin, a Japanese randomized trial showed a statistically significant survival advantage over cisplatin/etoposide in chemotherapy-naive patients with extensive-stage disease. This represents the first major advance in the treatment of extensive-stage SCLC in 20 years. Randomized trials in the United States are underway to confirm these impressive results. Meanwhile, trials incorporating irinotecan and cisplatin into treatment regimens for limited-stage disease are being conducted. Furthermore, irinotecan-containing regimens with other agents such as carboplatin, etoposide, and paclitaxel in first- or second-line therapies for SCLC are being evaluated. Preliminary results are encouraging. This article will highlight the exciting results achieved with irinotecan in SCLC and discuss its promising future in this disease.

KW - Chemotherapy

KW - CPT-11

KW - Irinotecan

KW - Lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0034964131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034964131&partnerID=8YFLogxK

M3 - Article

VL - 2

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - SUPPL. 2

ER -